in-PharmaTechnologist RSS

Reimportation is “legislative madness”

nick.taylor@decisionnews.com — Thu, 19 Nov 2009 11:00:00 +0100

It is “legislative madness” to allow reimportation in the US, according to the chair of EAASM who spoke at AAPS about Europe’s “porous supply chain” and how it could affect the standard of medicines in the States.

UCB to cut 200 jobs in UK and Belgium

gareth.macdonald@decisionnews.com — Thu, 19 Nov 2009 11:00:00 +0100

Belgian biotech UCB is to reduce workforce 2 per cent as part of R&D restructuring plan according to various reports.

Vaccine demand a friend to Pall in Q1; but sales still fall 5.4%

gareth.macdonald@decisionnews.com — Thu, 19 Nov 2009 11:00:00 +0100

Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.

People on the move: pharma jobs

nick.taylor@decisionnews.com — Thu, 19 Nov 2009 11:00:00 +0100

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Xoma and Watson Pharmaceuticals, plus a new role for Fred Hasaan.

BASF talks novel excipients

nick.taylor@decisionnews.com — Wed, 18 Nov 2009 11:00:00 +0100

The FDA encourages innovation in excipients to develop new drugs or improve approved therapeutics and IPEC is helping to drive acceptance of these novel products, according to BASF.

Failed anti-depressant flibanserin reborn as female “Viagra”?

gareth.macdonald@decisionnews.com — Wed, 18 Nov 2009 11:00:00 +0100

Boehringer Ingelheim looks set for a significant windfall with results from Phase III trials indicating that its drug flibanserin can boost sexual desire in women, raising the prospect of a female equivalent to Pfizer’s Viagra.

Reaxa gets UK grant for Ni EnCat scale-up

gareth.macdonald@decisionnews.com — Wed, 18 Nov 2009 11:00:00 +0100

UK process technologies firm Reaxa has received a £146K (€164K) R&D grant from the Northwest Regional Development Agency (NWDA) to scale-up production of its EnCat nickel catalyst.

GBM trial to deliver Avastin across BBB

nick.taylor@decisionnews.com — Wed, 18 Nov 2009 11:00:00 +0100

Neurosurgeons have developed and used a novel intra-arterial (IA) technique to deliver Avastin (bevacizumab) directly into a malignant brain tumour, potentially administering a higher dose with reduced toxicity.

API quality enforcement in disarray; Villax

nick.taylor@decisionnews.com — Tue, 17 Nov 2009 11:00:00 +0100

Regulatory enforcement efforts to tackle counterfeit and substandard APIs are in disarray, according to Guy Villax, CEO of Hovione, who spoke at AAPS about the scale of the problem.

Cafosa launches gum delivery excipient

gareth.macdonald@decisionnews.com — Tue, 17 Nov 2009 11:00:00 +0100

Spanish ingredient supplier Cafosa has launched a new directly compressible pharmaceutical excipient for medicated chewing gums that, it claims, can boost patient compliance.